Business Wire

NTT Communications' SD-WAN Gives McLaren Racing an Edge for 2018 Season

Jaa

McLaren Formula 1 TEAM (McLaren), a pioneering leader in Formula 1 motor racing for more than 50 years, and NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that McLaren will adopt SD-WAN (software-defined wide-area network) technology from NTT Com to connect the McLaren Technology Centre with racing circuits in 21 countries during the 2018 season. The decision follows a successful test deployment of the technology during the 2017 Japan Grand Prix, when McLaren was able to send 100GB of data during a race from Japan to the UK via NTT Com’s SD-WAN.

NTT Com’s SD-WAN uses software to control the WAN, providing McLaren with quick, secure, reliable and flexible management of data traffic flows. A variety of traffic can be sent via different connections, such as internet, mobile and MPLS, depending on time, priority and current network speed. This flexibility allows the priority routing of key data, such as telemetry and video, at critical points. Also, NTT Com’s service includes a dashboard screen to visualize data-traffic status during a race. McLaren can grasp network availability and required data bandwidth at a glance to optimize data transmission during a race, giving them an edge in the real-time formation, adjustment and deployment of in-race strategy.

Dr. Shin Miyakawa, Vice President, IoT Office / McLaren Taskforce was particularly pleased with the genesis and evolution of the project. “One of our R&D engineers attended a pre-season practice in Barcelona in 2017 and noticed occasional video jitter on screens in a garage, which made him wonder about the data bottlenecks causing the problem. At his suggestion, we tested our SD-WAN during the Suzuka 2017 race and the results were very successful. We engineered a solution for the 2018 season that McLaren will now use across the team. I’m very pleased with the success of our technology partnership.”

During a keynote speech at the Mobile World Congress in February 2018, two-time F1 world champion Fernando Alonso spoke about the growing importance of data for both machine and driver performance: “Each car provides more data every single second than you can imagine. Every single movement we do in the car, every steering wheel input, every throttle input, every brake pressure input is transmitted immediately in real time to the engineers in the garage.”

“Technology is such an important part of racing,” said Zak Brown, Executive Director of McLaren Technology Group. “SD-WAN is one of a number of marginal gains we are seeing from our technology partnership with NTT Communications. Because SD-WAN offers us more control over data flows during crucial moments, it gives us an edge. I also think it proves the willingness of our Technology Partners to deliver, to bring their expertise to the party, with the ultimate goal of driving the team faster.”

For more about NTT Communications SD-WAN, or to contact us: ntt-sdwan.com

Attachemnt1. Secure ICT Infrastructure
Attachemnt2. Race Schedule for 2018 Season

About McLaren Formula 1 TEAM

New Zealand racing driver Bruce McLaren founded the McLaren racing team in 1963. Since 1966, when it entered its first Formula 1 race, McLaren has won 20 world championships and over 180 grands prix. It has also won the Le Mans 24 Hours and the Indy 500 the two biggest races in the world.

Since those early days, the McLaren Technology Group has developed into one of international sport’s most successful competitors, become a globally renowned automotive manufacturer, and earned recognition as one of the most illustrious high-technology brands in the world.

The McLaren team campaigns the 2018 FIA Formula 1 World Championship with double-world champion Fernando Alonso and Stoffel Vandoorne.

They drive the McLaren-Renault MCL33.

About NTT Communications Corporation

NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company’s worldwide infrastructure, including the leading global tier-1 IP network, the Arcstar Universal One™ VPN network reaching over 190 countries/regions, and over 140 secure data centers worldwide. NTT Communications’ solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com

Contact information

For more information
McLaren Technology Group
Mr. Tim Bampton
Group Communications Director
tim.bampton@mclaren.com
or
NTT Communications Corporation
Mr. Ryu Kanishima
Technology Development
sd-wan@ntt.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)18.6.2018 14:00Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective from July 1. The innovative, long-term access agreement also provides a framework for the assessment and access of our future CF medicines. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex. “We commend the Swedish authorities for partnering with us on an innovative, long-term access agreement. In countries where Vertex remains actively involved in reimbursement discussions, we encourage these health authorities and governments to match the commitment

LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00Tiedote

LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06Tiedote

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53Tiedote

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme